Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 20/20 | 0.69 |
| ▸ | CHUK | O15111 | 4/20 | 0.69 |
| ▸ | EPHA3 | P29320 | 3/20 | 0.69 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14281201 | 0.89 | IKBKB (0.68) | IKBKBCHUKEPHA3NTRK1PDGFRA | |
| SCHEMBL4903314 | 0.83 | IKBKB (0.62) | IKBKBCHUKEPHA3NTRK1PDGFRA | |
| SCHEMBL4895872 | 0.82 | IKBKB (0.57) | IKBKBCHUKEPHA3NTRK1PDGFRA | |
| SCHEMBL4656913 | 0.82 | IKBKB (1.00) | IKBKBCHUKEPHA3NTRK1PDGFRA | |
| SCHEMBL4902514 | 0.81 | IKBKB (0.48) | IKBKBCHUKEPHA3NTRK1PDGFRA | |
| SCHEMBL4656962 | 0.79 | IKBKB (0.93) | IKBKBCHUKEPHA3NTRK1PDGFRA | |
| SCHEMBL4903242 | 0.77 | IKBKB (0.62) | IKBKBCHUKEPHA3NTRK1PDGFRA | |
| SCHEMBL4892342 | 0.76 | IKBKB (0.61) | IKBKBCHUKEPHA3NTRK1PDGFRA | |
| SCHEMBL4895363 | 0.76 | IKBKB (0.61) | IKBKBCHUKEPHA3NTRK1PDGFRA | |
| SCHEMBL14111042 | 0.73 | IKBKB (0.85) | IKBKBCHUKEPHA3NTRK1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1673374-A2 | SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005035537-A2 | SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | LTC4S, NQO1, CBR3 | IKBKB 178/4885CHUK 127/4885EPHA3 4565/4885 |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | LTC4S, NQO1, CBR3 | IKBKB 178/4885CHUK 127/4885EPHA3 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.